新型α2-肾上腺素能受体拮抗剂对α2A-和α2B-肾上腺素能受体亚型具有选择性。
Novel alpha 2-adrenoceptor antagonists show selectivity for alpha 2A- and alpha 2B-adrenoceptor subtypes.
作者信息
Young P, Berge J, Chapman H, Cawthorne M A
机构信息
Beecham Pharmaceuticals Research Division, Epsom, Surrey, U.K.
出版信息
Eur J Pharmacol. 1989 Sep 22;168(3):381-6. doi: 10.1016/0014-2999(89)90801-7.
Pharmacological characterization of mammalian alpha 2-adrenoceptors in various tissues and species has provided evidence for the existence of two alpha 2-adrenoceptor subtypes. These subtypes can be defined in rat and human tissues by prazosin which is alpha 2B selective and oxymetazoline which is alpha 2A selective. In addition to these agents, two types of alpha 2-adrenoceptor antagonists are described which show high affinity and selectivity for the alpha 2A-adrenoceptor and the alpha 2B-adrenoceptor respectively.
对各种组织和物种中哺乳动物α2肾上腺素能受体的药理学特性研究为两种α2肾上腺素能受体亚型的存在提供了证据。在大鼠和人类组织中，这些亚型可通过对α2B具有选择性的哌唑嗪和对α2A具有选择性的羟甲唑啉来定义。除了这些药物外，还描述了两种α2肾上腺素能受体拮抗剂，它们分别对α2A肾上腺素能受体和α2B肾上腺素能受体表现出高亲和力和选择性。
Zotero 插件